Pharmaceutical

STAT+: Pharmalittle: German regulator eyes Ozempic expo...

The German drug regulator is considering an export ban on Novo Nordisk's diabete...

STAT+: To get things done fast at FDA: ‘Don’t tell anyb...

The Food and Drug Administration’s top cancer drug regulator doesn’t always ask ...

STAT+: Hospitals say violence against health workers is...

As health care workers face higher risk of violence, hospitals are turning to sy...

STAT+: Life scientists’ flight to biotech labs stalls i...

The seismic shift in researchers from academic to biotech labs is already having...

Opinion: Hospital systems have to decide: Do they want ...

Hospital systems have to decide: Do they want to be Apple or Android?

Opinion: Listen: The true costs of mediocre insurance p...

The true costs of mediocre insurance plans for medical students.

UnitedHealth faces class action lawsuit over algorithmi...

A class action lawsuit was filed against UnitedHealth and a subsidiary alleging ...

Fresh produce access boosts health outcomes among diabe...

Advocates say that programs that treat food as medicine could go a long way towa...

STAT+: ‘I never realized what people go through’: Docto...

After a stage 4 lung cancer diagnosis, former doctor and hospital CEO James Fana...

STAT+: New NIH head says government has fallen behind p...

NIH Director Monica Bertagnolli said it’s a “failure” that enrollment in governm...

What health policies could hitch a ride on a spending b...

What health policies could hitch a ride on a spending bill? We've assembled the ...

A letter from the executive editor: STAT’s investigatio...

A STAT investigation reveals that UnitedHealth pursued a strategy to pressure it...

Nouscom raises $72m in Series C financing round to deve...

Swiss biotech Nouscom has raised €67.5m ($72m) in a Series C funding round co-l...

FDA oversees rise in awarded orphan drug designations f...

Concerns have been raised over the suitability of current FDA-approved treatmen...

AstraZeneca announces GLP-1 combo to treat obesity and ...

AstraZeneca has announced its strategy for the cardiometabolic market, in parti...

ProKidney amends Phase III protocol in light of Phase I...

The Phase II interim data shows ProKidney’s autologous cell therapy React (...